WO2005107752A3 - Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin - Google Patents

Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin Download PDF

Info

Publication number
WO2005107752A3
WO2005107752A3 PCT/EP2005/005176 EP2005005176W WO2005107752A3 WO 2005107752 A3 WO2005107752 A3 WO 2005107752A3 EP 2005005176 W EP2005005176 W EP 2005005176W WO 2005107752 A3 WO2005107752 A3 WO 2005107752A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
receptor antagonist
diseases associated
opioid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/005176
Other languages
French (fr)
Other versions
WO2005107752A2 (en
Inventor
Helmut Schmidhammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcasynn Pharmaceuticals GmbH
Original Assignee
Alcasynn Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007512104A priority Critical patent/JP2007537198A/en
Priority to AT05742958T priority patent/ATE445401T1/en
Priority to US11/579,900 priority patent/US20070167474A1/en
Priority to DE602005017145T priority patent/DE602005017145D1/en
Priority to CN2005800181491A priority patent/CN1997369B/en
Priority to CA002566398A priority patent/CA2566398A1/en
Priority to EP05742958A priority patent/EP1755604B1/en
Priority to MXPA06013128A priority patent/MXPA06013128A/en
Application filed by Alcasynn Pharmaceuticals GmbH filed Critical Alcasynn Pharmaceuticals GmbH
Priority to AU2005239831A priority patent/AU2005239831A1/en
Publication of WO2005107752A2 publication Critical patent/WO2005107752A2/en
Publication of WO2005107752A3 publication Critical patent/WO2005107752A3/en
Anticipated expiration legal-status Critical
Priority to NO20065551A priority patent/NO20065551L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Morphinane derivatives of the formula (I) their pharmaceutically acceptable salts are provided for use as medicaments for the treatment and/or prevention of disorders associated with the target calcineurin.
PCT/EP2005/005176 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin Ceased WO2005107752A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP05742958A EP1755604B1 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
US11/579,900 US20070167474A1 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
DE602005017145T DE602005017145D1 (en) 2004-05-12 2005-05-12 USE OF OPIOID RECEPTOR ANTAGONISTS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES RELATED TO THE TARGET CALCINEURIN
CN2005800181491A CN1997369B (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
CA002566398A CA2566398A1 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
JP2007512104A JP2007537198A (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and / or treatment of targeted calcineurin related diseases
AT05742958T ATE445401T1 (en) 2004-05-12 2005-05-12 USE OF OPIOID RECEPTOR ANTAGONISTS TO PREVENT AND/OR TREAT DISEASES RELATED TO THE TARGET CALCINEURIN
MXPA06013128A MXPA06013128A (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin.
AU2005239831A AU2005239831A1 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
NO20065551A NO20065551L (en) 2004-05-12 2006-12-01 Use of opoid receptor antagonist compounds for the prevention and / or treatment of diseases associated with painted calcineurin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011293.0 2004-05-12
EP04011293A EP1595541A1 (en) 2004-05-12 2004-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Publications (2)

Publication Number Publication Date
WO2005107752A2 WO2005107752A2 (en) 2005-11-17
WO2005107752A3 true WO2005107752A3 (en) 2006-06-01

Family

ID=34924978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005176 Ceased WO2005107752A2 (en) 2004-05-12 2005-05-12 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Country Status (14)

Country Link
US (1) US20070167474A1 (en)
EP (2) EP1595541A1 (en)
JP (2) JP2007537198A (en)
CN (1) CN1997369B (en)
AT (1) ATE445401T1 (en)
AU (1) AU2005239831A1 (en)
CA (1) CA2566398A1 (en)
DE (1) DE602005017145D1 (en)
ES (1) ES2334042T3 (en)
MX (1) MXPA06013128A (en)
NO (1) NO20065551L (en)
RU (1) RU2006143770A (en)
WO (1) WO2005107752A2 (en)
ZA (1) ZA200609337B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122436A2 (en) 2008-03-31 2009-10-08 Sun Pharmaceutical Industries Ltd. An improved process for the preparation of morphinane analogues
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2641588B1 (en) * 2012-03-23 2017-11-22 Induchem Holding AG Use of agonists of delta opioid receptor in cosmetic and dermocosmetic field
KR101694879B1 (en) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 Non-immuno suppressive FK506 analogues with neuroregenerative activity and the use thereof
EP3197346B1 (en) * 2014-09-22 2020-02-26 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614898A1 (en) * 1992-09-29 1994-09-14 Toray Industries, Inc. Indole derivative, process for producing the same, and medicinal use thereof
WO1995031463A1 (en) * 1994-05-18 1995-11-23 Astra Aktiebolag New antagonist compounds
WO2004026819A2 (en) * 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030060771A (en) * 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 Topical anesthetic/opioid formulations and uses thereof
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614898A1 (en) * 1992-09-29 1994-09-14 Toray Industries, Inc. Indole derivative, process for producing the same, and medicinal use thereof
WO1995031463A1 (en) * 1994-05-18 1995-11-23 Astra Aktiebolag New antagonist compounds
WO2004026819A2 (en) * 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIYASHEV, DAUREN ET AL: "Novel delta-opioid-receptor-selective ligands in the 14-alkoxy-substituted indolo- and benzofuromorphinan series", HELVETICA CHIMICA ACTA , 84(7), 2015-2021 CODEN: HCACAV; ISSN: 0018-019X, 2001, XP008035570 *
LAHSEN, JOAQUIN ET AL: "Structure-activity relationship study of nonpeptide .delta.-opioid receptor ligands", HELVETICA CHIMICA ACTA , 84(11), 3299-3305 CODEN: HCACAV; ISSN: 0018-019X, 2001, XP008035577 *
SPETEA M ET AL: "Binding, pharmacological and immunological profiles of the delta-selective opioid receptor antagonist HS 378.", LIFE SCIENCES. 31 AUG 2001, vol. 69, no. 15, 31 August 2001 (2001-08-31), pages 1775 - 1782, XP008035572, ISSN: 0024-3205 *

Also Published As

Publication number Publication date
EP1595541A1 (en) 2005-11-16
JP2007537198A (en) 2007-12-20
ZA200609337B (en) 2008-08-27
ES2334042T3 (en) 2010-03-04
RU2006143770A (en) 2008-06-20
DE602005017145D1 (en) 2009-11-26
AU2005239831A1 (en) 2005-11-17
WO2005107752A2 (en) 2005-11-17
US20070167474A1 (en) 2007-07-19
CN1997369B (en) 2011-12-21
MXPA06013128A (en) 2007-04-27
CN1997369A (en) 2007-07-11
CA2566398A1 (en) 2005-11-17
EP1755604B1 (en) 2009-10-14
JP2012254986A (en) 2012-12-27
NO20065551L (en) 2007-02-05
ATE445401T1 (en) 2009-10-15
EP1755604A2 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2007002667A3 (en) Azaindazole compounds and methods of use
WO2007135527A3 (en) Benzimidazolyl compounds
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
WO2006014665A3 (en) Arylpyrrolidine derivatives as nk-1/ssri antagonists
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
MX2009006613A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
TW200607807A (en) Macrocyclic beta-secretase inhibitors
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2007073432A3 (en) Piperidine derivatives and methods of use
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
WO2007092157A9 (en) 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2005107752A3 (en) Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.
WO2008004100A3 (en) Therapeutic compounds
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2006064228A3 (en) Thiazolopyramidine compounds for the modulation of chemokine receptor activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580018149.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200609337

Country of ref document: ZA

Ref document number: 2566398

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013128

Country of ref document: MX

Ref document number: 2005742958

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007512104

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005239831

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005239831

Country of ref document: AU

Date of ref document: 20050512

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 551864

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2005239831

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006143770

Country of ref document: RU

Ref document number: 4552/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11579900

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005742958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11579900

Country of ref document: US